Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon

Thrombosis and Haemostasis

Volumn 100, Issue 6, 2008, Pages 1052-1057

  Beinema, Maarten ^a   Brouwers, Jacobus R B J ^b   Schalekamp, Tom ^c   Wilffert, Bob ^b  

^a DEVENTER HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Clinical trials; Oral anticoagulants; Pharamacogenetics; Pharmacodynamics

Indexed keywords

ACENOCOUMAROL; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9; LORNOXICAM; MENADIONE EPOXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOREDUCTASE; PHENPROCOUMON; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE C1; WARFARIN;

ALLELE; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM;

ACENOCOUMAROL; ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BLOOD COAGULATION; DRUG INTERACTIONS; DRUG MONITORING; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; PHENPROCOUMON; POLYMORPHISM, GENETIC; RISK ASSESSMENT; WARFARIN;

EID: 57349097594     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0116     Document Type: Review

References (69)

1. Cranenburg ECM, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98: 120-125.
2. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP et al. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Throm Haemost 1996; 76: 12-16.
3. Torn M, Bollen WL, van der Meer FJ, et al. Risks of anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527-1532.
4. Zu Schwabedissen CM, Mevissen V, Schmitz F et al. Obesity is associated with a slow response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. Eur J Clin Pharmacol 2006; 62: 713-720.
5. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998; 23: 247-255.
6. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450 linked drug metabolism in humans : an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331-339.
7. Oden A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002; 325: 1073-1075.
8. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol 2006; 13: 357-361.
9. Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006; 6: 223-227.
10. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-1270.
11. Daly AK, King BP. Pharamcogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247-252.
12. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603.
13. Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002; 194: 267-273.
14. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the Cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding Complications. Lancet 1999; 353: 717-719.
15. Margaglione M, Colaizzo D, Brancaccio V, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-778.
16. Higashi MK, Veenstra DL, Kondo LM et al. Association Between CYP2C9 Genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 2002; 287: 1690-1698.
17. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111: 4106-4112.
18. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293
19. Oldenburg J, Bevans CG, Fregin A, et al.. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-578.
20. Schwarz UI, Ritchie MD, Bradford Y et al.. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
21. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2008; prepub online doi:10.1182/blood-2008-04-149070.
22. Daly AK, Aithal GP. Genetic regulation of warfarin metabolism and response. Semin Vasc Med 2003; 3: 231-238.
23. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006; 22: 191-197.
24. Wilms EB, Touw DJ, Conemans JM, et al. A new VKORC1 allelic variant -p.Trp59Arg- in a patient with partial resistance to acenocoumarol and phenprocoumon. J Thromb Haemost 2008; 6: 1224-1226.
25. Loebstein R, Dvoskin I, Halkin H, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007; 6: 2477-2480.
26. Lal S, Jada SR, Xiang X, et al. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin Pharmacokinet 2006; 45: 1189-1200.
27. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-1290.
28. Thijssen HH, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther 2003; 74: 61-68.
29. Morin S, Bodin L, Loriot MA, et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther 2004; 75: 403-414.
30. Takahashi H, Wilkinson GR, Padrini R, et al. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 2004; 75: 376-380.
31. Thijssen HH, Drittij MJ, Vervoort LM, et al. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70: 292-298.
32. Verstuyft C, Morin S, Robert A, et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001; 11: 735-737.
33. Andre-Kerneis E, Leroy-Matheron C, Gouault-Heilmann M. Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9. Blood Coagul Fibrinolysis 2003; 14: 761-764.
34. Thijssen HH, Verkooijen IW, Frank HL. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics 2000; 10: 757-760.
35. Thijssen HH, Drittij MJ, Vervoort LM, et al. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70: 292-298.
36. Hermida J, Zarza J, Alberca I, et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 2002; 99: 4237-4239.
37. Visser LE, van Vliet M, van Schaik RH, et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004; 14: 27-33.
38. Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, et al. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006; 133: 183-187.
39. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
40. Schalekamp T, Brassé BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80: 13-22.
41. Rettie AE, Farin FM, Beri NG, et al. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol 2006; 62: 617-620.
42. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44: 1227-1246.
43. Ufer M, Svensson JO, Krausz KW, et al. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004; 60: 173-182.
44. Kamerer B, Kahlich R, Ufer M, et al. Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometic identification of two novel metabolites in human plasma and liver microsomes. Anal Bioanal Chem 2005; 383: 909-917.
45. Ufer M, Kammerer B, Kahlich R et al. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 2004; 34: 847-859.
46. He M, Korzekwa KR, Jones JP, et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372: 16-28.
47. Ufer M. Effects of CYP2C9 polymorphisms on phenprocoumon anticoaglation status (letter). Clin Pharmacol Ther 2005; 77: 335.
48. Toon S, Heimark LD, Trager WF, et al. Metabolic fate of phenprocoumon in humans. J Pharm Sci 1985; 74: 1037-1040.
49. Kirchheiner J, Ufer M, Walter EC, et al.. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14: 19-26.
50. He M, Korzekwa KR, Jones JP, et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372: 16-28.
51. Schalekamp T, Brassé BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007; 81: 185-193.
52. Hummers-Pradier E, Hess S, Adham IM et al. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 2003; 59: 213-219.
53. Visser LE, van Schaik RH, van Vliet M, et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92: 61-66.
54. Fihn SD, Gadisseur AA, Pasterkamp E, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 260-266.
55. Gadisseur AP, Van der Meer FJ, Adriaansen HJ et al. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117: 940-946.
56. Kohl C, Steinkellner M. Prediction of pharmacokinetic drug-drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 2000; 28: 161-168.
57. Visser LE, van Schaik RH, van Vliet M, et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005; 77: 479-485.
58. Van Dijk KN, Plat AW, van Dijk AA, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 2004; 91: 95-101.
59. Zarza J. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9. Thromb Haemost 2003; 90: 161-162.
60. Beinema MJ, de Jong PH, Salden HJ, et al. The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery. Mol Diagn Ther 2007; 11: 123-128.
61. Masche UP, Rentsch KM, von Felten A , et al. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol 1999; 54: 857-864.
62. Gage BF, Lesko LL. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25: 45-51.
63. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 247-252.
64. Schwarz UI, Stein CM. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther 2006; 80: 7-12.
65. Shurin SB, Nabel EG. Pharmacogenomics - Ready for prime time? N Engl J Med 2008; 358: 1061-1063.
66. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93: 700-705.
67. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 2007; 120: 1-10.
68. Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and advherance to guidelines. Pharmacoeconomics 2008; 26: 569-587.
69. You JHS, Chan FWh, Wong RSM, et al. The potential clinical and economic outcomes of pharmacogenetics-orientated management of warfarin therapy - a decision analysis. Thromb Haemost 2004; 92: 590-597.